Irhythm Technologies, Inc.

Health Care
Medical/Dental Instruments
www.irhythmtech.com

Moat Score
Safety Score

Market Cap $2.65B
PE -18
Debt $645.82M
Cash $527.89M
EV $2.77B
FCF -$72.43M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$150.66M
EBIT	-$149.87M
ROE	-210%
ROA	-16%
FCF	-$72.43M
Equity	$71.77M
Growth Stability	1
PE	-17.61
PB	36.97
P/FCF	-36.63
P/S	4.74
Price/Cash	0.2
Debt/Equity	9
Debt/FCF	-8.92
Net Margins	-26%
Gross Margins	68%
Op. Margins	-27%
Sales Growth YoY	18%
Sales Growth QoQ	-0%
Sales CAGR	34%
Equity CAGR	14%
Earnings Growth YoY	70%

Earnings Growth QoQ	130%
Sales CAGR 5Y	23%
Equity CAGR 5Y	-11%
Earnings CAGR 3Y	22%
Sales CAGR 3Y	22%
Equity CAGR 3Y	-35%
Market Cap	$2.65B
Revenue	$560.03M
Assets	$909.69M
Total Debt	$645.82M
Cash	$527.89M
Shares Outstanding	31.15M
EV	2.77B
Moat Score	2%
Safety Score	51%
Working Capital	527.81M
Current Ratio	6.27
Gross Profit	$379.89M
Shares Growth 3y	2%
Equity Growth QoQ	-28%
Equity Growth YoY	-67%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. The companys portfolio include ambulatory cardiac monitoring services on a platform called the Zio service which combines an easy-to-wear and unobtrusive biosensor that can be worn for up to 14 consecutive days with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company derived its revenue from the United States.

SEC Filings

Direct access to Irhythm Technologies, Inc. (IRTC) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Irhythm Technologies, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Irhythm Technologies, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Irhythm Technologies, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Irhythm Technologies, Inc..

Years

Calculation mode

= -$724M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$72M	-$72M	-$72M	-$72M	-$72M	-$72M	-$72M	-$72M	-$72M	-$72M	-$72M	-$724M
DCF		-$66M	-$60M	-$54M	-$49M	-$45M	-$41M	-$37M	-$34M	-$31M	-$28M	-$279M
Value	-$724M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-73%	-63%	-33%	-30%	-33%	-25%	-17%	-31%	-28%	-25%	-26%
ROA	-	-57%	-11%	-20%	-36%	-17%	-8%	-22%	-25%	-28%	-16%
ROE	-	22%	-23%	-37%	-89%	-40%	-13%	-36%	-48%	-59%	-210%

Bad Net Margins (-26.19%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-1.54	-2.39	-2.5	-1.02	-0.83	-1.21	-0.32	-0.66	-0.39	-8.92
Debt over Equity	-	-0.3	0.5	0.58	0.64	0.26	0.1	0.08	0.15	0.17	9
Growth Stability	-	-	-	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (-8.92)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Bad Debt/Equity ratio (9)

The company is overleveraged and has a bad balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	66%	77%	54%	50%	46%	24%	22%	27%	20%	23%
Earnings YoY growth	-	44%	-8%	41%	64%	13%	-20%	131%	15%	6%	-
Equity YoY growth	-	26%	-191%	-14%	-32%	149%	152%	-18%	-14%	-12%	-11%
FCF YoY growth	-	22%	-2%	-5%	85%	24%	-35%	141%	-20%	71%	-